Limited company (société anonyme) with a Management Board (directoire)
and a Supervisory Board (conseil de surveillance) with share capital of €1,557,005.50
Registered Office: Prologue-Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France
Toulouse Trade and Companies Register (RCS) B 439 489 022
Disclosure of the total number of voting rights and
shares composing the share capital
Persuant to Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF – Autorité des Marchés Financiers)
As of December 31st, 2016
|Total number of outstanding shares||15,570,055|
|Theoretical voting rights (1)||15,570,055|
Shares without voting rights
|Treasury registered shares (2)||0|
|Treasury bearer shares (3)||23,800|
|Exercisable voting rights
= (1) - [(2) + (3) + (4)]
Genticel's versatile platform, Vaxiclase, is well suited for the development of various immunotherapies. A partnership on the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Pvt. Ltd. (Serum Institute), the largest producer of vaccine dose worldwide. This agreement covers territories in emerging markets only, and could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. In November 2016, the last preclinical milestone was reached, opening the path to formal preclinical testing prior to clinical development and subsequent commercialization.
On December 22nd 2016, Genticel signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel's shareholders at a meeting expected to be held in the first quarter of 2017, Genkyotex's shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex's shareholders will hold 80% of Genticel's share capital & voting rights (on a non-diluted basis).
Genkyotex is developing a portfolio of NADPH oxidase (NOX) oral small molecule inhibitors, which have therapeutic potential for the treatment of multiple significant clinical indications with substantial unmet need, including fibrosis, inflammatory pain, angiogenesis, cancer growth, and neurodegeneration. Genkyotex is currently developing two clinical stage, first-in-class NOX inhibitors and is conducting research on several other pre-clinical molecules.
More information at www.genticel.com
Forward Looking Statement
This press release contains forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French “Autorité des Marchés Financiers”, including in the Company's Annual Report for the year ended December 31, 2015 and future filings and reports by the Company which are available on the Company's website.. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Genticel undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
|EU INVESTORS||US INVESTORS||MEDIA|
+33 1 44 71 94 92
+1 212 915 2578
+33 6 64 18 99 59 / +33 6 47 38 90 04